Business
Bell Potter thinks the Mesoblast (ASX:MSB) share price can run higher
Well, 2020 was yet another rollercoaster ride for the Mesoblast Limited (ASX: MSB) share price, as good and bad news pushed and pulled on the company’s shares.
The latest piece of disappointing news from Mesoblast was on its remestemcel-L product. This is used for ventilator dependent patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection.
The Mesoblast share price spiralled 45% lower when the trial was reported to be unlikely to meet the 30-day mortality reduction endpoint at the planned 300 patient enrolment.
Despite the trial shortcomings, Bell Potter maintained a speculative buy recommendation on Mesoblast shares on 23 December 2020. The broker updated its Mesoblast share…
-
General24 hours ago“Accumulation of defects”. A-G report scathing on Navy shipbuilding
-
General23 hours agoG7 agrees to avoid higher taxes for US, UK companies
-
Noosa News22 hours agoFood supply chain system costs farmers and regions millions of dollars
-
Business22 hours agoBuy and hold NDQ and these ASX ETFs for 10 years